HeartBeam (Nasdaq:BEAT) today announced that a study of its synthesized 12-lead electrocardiogram (ECG) met its clinical ...

HeartBeam rolled out an application for its 12-lead ECG synthesis software to the FDA, based on the data from the study.

(RTTNews) - HeartBeam, Inc., (BEAT), a medical technology company, Tuesday said its synthesized 12-lead electrocardiogram (ECG) met the clinical endpoints in the VALID-ECG pivotal study.

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing ...

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company ...